

# COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry

NCT05046002

---

Status	RECRUITING
Sponsor	Ottawa Heart Institute Research Corporation
Enrollment	400 participants

## Key Eligibility Criteria

---

### Inclusion (13)

- All patients eligible for vaccination with a COVID-19 vaccine,
- At least one cardiac symptom of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath/dyspnea/pain with breathing, palpitations, diaphoresis, syncope, or sudden death.
- OR At least two non-specific symptoms within 42 days of receiving a COVID-19 vaccination. These symptoms include fatigue, abdominal pain, dizziness or syncope, edema, or cough.
- OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI)
- At least one of the following:  
... and 8 more (see full listing online)

### Exclusion (2)

- Clear alternative diagnosis or explanation for the symptoms and findings (e.g. infectious myocarditis such as Lyme carditis). Note: Work-up of alternative diagnosis is dependent on clinical presentation e.g. Lyme carditis (e.g. endemic area, season, bullseye rash) or autoimmune heart disease (e.g. arthritis, rash, recurrence).
- Symptoms after 42 days of vaccination.

## Locations (1 total)

---

University of Ottawa Heart Institute, Ottawa, Ontario, Canada